• Syndax reported third-quarter 2026 revenue of $83.3 million in its corporate presentation, with net loss narrowing to $49.4 million from $60.7 million.
• Revuforj net revenue rose 90% year over year to $60.7 million; Niktimvo collaboration revenue reached $22.6 million.
• Cash and equivalents totaled $551.1 million; full-year R&D and SG&A expense guidance was $400 million, excluding $50 million in expected stock-option expense.
• A revumenib myelofibrosis trial is expected to begin in the fourth quarter of 2026, with initial data anticipated in second-half 2027.
• SNDX-4321's investigational new drug application is expected by year-end 2026; a Phase 1 lung cancer trial is planned for 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.